Literature DB >> 22231396

Novel targeted therapy for acute myeloid leukemia with a dual FLT3 and JAK2 inhibitor.

Yin-jun Lou1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22231396      PMCID: PMC4010335          DOI: 10.1038/aps.2011.206

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


× No keyword cloud information.
  7 in total

Review 1.  Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms.

Authors:  Brady L Stein; John D Crispino; Alison R Moliterno
Journal:  Curr Opin Oncol       Date:  2011-11       Impact factor: 3.645

2.  SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.

Authors:  S Hart; K C Goh; V Novotny-Diermayr; C Y Hu; H Hentze; Y C Tan; B Madan; C Amalini; Y K Loh; L C Ong; A D William; A Lee; A Poulsen; R Jayaraman; K H Ong; K Ethirajulu; B W Dymock; J W Wood
Journal:  Leukemia       Date:  2011-06-21       Impact factor: 11.528

3.  Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Authors:  Nikhil Wagle; Caroline Emery; Michael F Berger; Matthew J Davis; Allison Sawyer; Panisa Pochanard; Sarah M Kehoe; Cory M Johannessen; Laura E Macconaill; William C Hahn; Matthew Meyerson; Levi A Garraway
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

Review 4.  FLT3 inhibitors: a story of the old and the new.

Authors:  Amir Fathi; Mark Levis
Journal:  Curr Opin Hematol       Date:  2011-03       Impact factor: 3.284

Review 5.  Acute promyelocytic leukemia: from highly fatal to highly curable.

Authors:  Zhen-Yi Wang; Zhu Chen
Journal:  Blood       Date:  2008-03-01       Impact factor: 22.113

6.  Recurring mutations found by sequencing an acute myeloid leukemia genome.

Authors:  Elaine R Mardis; Li Ding; David J Dooling; David E Larson; Michael D McLellan; Ken Chen; Daniel C Koboldt; Robert S Fulton; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Devin P Locke; Vincent J Magrini; Rachel M Abbott; Tammi L Vickery; Jerry S Reed; Jody S Robinson; Todd Wylie; Scott M Smith; Lynn Carmichael; James M Eldred; Christopher C Harris; Jason Walker; Joshua B Peck; Feiyu Du; Adam F Dukes; Gabriel E Sanderson; Anthony M Brummett; Eric Clark; Joshua F McMichael; Rick J Meyer; Jonathan K Schindler; Craig S Pohl; John W Wallis; Xiaoqi Shi; Ling Lin; Heather Schmidt; Yuzhu Tang; Carrie Haipek; Madeline E Wiechert; Jolynda V Ivy; Joelle Kalicki; Glendoria Elliott; Rhonda E Ries; Jacqueline E Payton; Peter Westervelt; Michael H Tomasson; Mark A Watson; Jack Baty; Sharon Heath; William D Shannon; Rakesh Nagarajan; Daniel C Link; Matthew J Walter; Timothy A Graubert; John F DiPersio; Richard K Wilson; Timothy J Ley
Journal:  N Engl J Med       Date:  2009-08-05       Impact factor: 91.245

7.  Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.

Authors:  S Hart; K C Goh; V Novotny-Diermayr; Y C Tan; B Madan; C Amalini; L C Ong; B Kheng; A Cheong; J Zhou; W J Chng; J M Wood
Journal:  Blood Cancer J       Date:  2011-11-11       Impact factor: 11.037

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.